Travere Therapeutics, Inc.
TVTX
$14.50
$1.017.49%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 65.98% | 69.56% | 68.08% | 33.95% | 53.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.98% | 69.56% | 68.08% | 33.95% | 53.58% |
| Cost of Revenue | 0.48% | -13.86% | -17.00% | -18.27% | 9.08% |
| Gross Profit | 152.81% | 138.71% | 93.64% | 69.60% | 35.00% |
| SG&A Expenses | 9.30% | -3.22% | -5.02% | -2.62% | 11.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.87% | -8.29% | -11.00% | 40.62% | 10.22% |
| Operating Income | 28.37% | 39.49% | 35.50% | -42.73% | 4.46% |
| Income Before Tax | 31.84% | 38.54% | 31.71% | -40.71% | -3.45% |
| Income Tax Expenses | -205.88% | -800.00% | 30.77% | 144.87% | 7.94% |
| Earnings from Continuing Operations | 31.97% | 38.65% | 31.67% | -40.80% | -3.46% |
| Earnings from Discontinued Operations | 100.25% | -100.02% | -104.64% | -101.01% | -107.96% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.17% | -136.36% | 17.78% | -57.60% | -36.99% |
| EBIT | 28.37% | 39.49% | 35.50% | -42.73% | 4.46% |
| EBITDA | 35.59% | 44.78% | 39.03% | -42.26% | 8.76% |
| EPS Basic | 38.50% | -135.67% | 19.37% | -39.30% | -15.02% |
| Normalized Basic EPS | 29.70% | 39.85% | 33.65% | -24.12% | 24.31% |
| EPS Diluted | 38.50% | -135.67% | 19.37% | -39.30% | -15.02% |
| Normalized Diluted EPS | 29.70% | 39.85% | 33.65% | -24.12% | 24.31% |
| Average Basic Shares Outstanding | 8.67% | 1.93% | 1.97% | 13.15% | 19.09% |
| Average Diluted Shares Outstanding | 8.67% | 1.93% | 1.97% | 13.15% | 19.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
